Michael Freeman
Stock Analyst at Raymond James
(2.67)
# 2,770
Out of 5,182 analysts
5
Total ratings
80%
Success rate
15.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Freeman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Assumes: Outperform | $14 | $6.94 | +101.73% | 1 | Jun 11, 2025 | |
| TECX Tectonic Therapeutic | Reinstates: Outperform | $76 | $28.75 | +164.35% | 1 | Jun 11, 2025 | |
| DYN Dyne Therapeutics | Assumes: Outperform | $37 | $18.04 | +105.10% | 1 | Jun 11, 2025 | |
| IRON Disc Medicine | Reinstates: Strong Buy | $89 | $68.85 | +29.27% | 1 | Jun 11, 2025 | |
| BHC Bausch Health Companies | Initiates: Market Perform | $8 | $5.58 | +43.37% | 1 | Jul 10, 2024 |
Wave Life Sciences
Jun 11, 2025
Assumes: Outperform
Price Target: $14
Current: $6.94
Upside: +101.73%
Tectonic Therapeutic
Jun 11, 2025
Reinstates: Outperform
Price Target: $76
Current: $28.75
Upside: +164.35%
Dyne Therapeutics
Jun 11, 2025
Assumes: Outperform
Price Target: $37
Current: $18.04
Upside: +105.10%
Disc Medicine
Jun 11, 2025
Reinstates: Strong Buy
Price Target: $89
Current: $68.85
Upside: +29.27%
Bausch Health Companies
Jul 10, 2024
Initiates: Market Perform
Price Target: $8
Current: $5.58
Upside: +43.37%